Carlyle faces regulatory divestiture demands in BASF deal; Incyte acquires Vega Therapeutics
The article discusses two major developments in the chemical and pharmaceutical industries: regulators are requiring Carlyle Group to divest assets as part of BASF's acquisition bid, and Incyte Corporation is acquiring Vega Therapeutics. The content focuses on corporate transactions, regulatory actions, and M&A activity in the life sciences and chemical sectors.
Key quotes
Regulators want Carlyle divestiture in BASF bid
Incyte to buy Vega Therapeutics
Here's what we're watching in the chemical and pharmaceutical industries this week
From the article
Here’s what we’re watching in the chemical and pharmaceutical industries this week
Continue reading on cen.acs.orgYou might also wanna read
Recent moves of note in and around the biotech and pharma industries
nature.com·13d ago
Inside the BoF and Clinuvel Community Lunch Exploring the Future of Skin Health
businessoffashion.com·1d agoCRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Bars·2d ago
Taking the Pulse of BioPharma: The Industry Today and Trends of Tomorrow
bioprocessintl.com·1h ago
AdBiotech Becomes No. 2 Shareholder of Pet Healthcare Firm Onhil
Seoul Economic Daily·2d ago
FDA Drug Regulator Accused of Targeting Former Business Associate's Pharmaceutical Company
The article discusses a scandal at the FDA involving a top drug regulator who allegedly used his position to target a former business associ
arstechnica.com·8mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.